PL1849470T5 - Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej - Google Patents

Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej

Info

Publication number
PL1849470T5
PL1849470T5 PL06712292.9T PL06712292T PL1849470T5 PL 1849470 T5 PL1849470 T5 PL 1849470T5 PL 06712292 T PL06712292 T PL 06712292T PL 1849470 T5 PL1849470 T5 PL 1849470T5
Authority
PL
Poland
Prior art keywords
alpha
trifluorothymidine
anticancer drug
drug containing
phosphorylase inhibitor
Prior art date
Application number
PL06712292.9T
Other languages
English (en)
Polish (pl)
Other versions
PL1849470T3 (pl
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1849470(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of PL1849470T3 publication Critical patent/PL1849470T3/pl
Publication of PL1849470T5 publication Critical patent/PL1849470T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06712292.9T 2005-01-26 2006-01-25 Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej PL1849470T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
PL1849470T3 PL1849470T3 (pl) 2017-11-30
PL1849470T5 true PL1849470T5 (pl) 2024-06-10

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06712292.9T PL1849470T5 (pl) 2005-01-26 2006-01-25 Lek przeciwrakowy zawierający alfa,alfa,alfa-trifluorotymidynę i inhibitor fosforylazy tymidynowej

Country Status (21)

Country Link
EP (1) EP1849470B2 (en:Method)
JP (1) JP5576591B2 (en:Method)
KR (1) KR101468216B1 (en:Method)
AU (1) AU2006209547C1 (en:Method)
BE (1) BE2017C028I2 (en:Method)
CA (1) CA2594713A1 (en:Method)
CY (2) CY1119393T1 (en:Method)
DK (1) DK1849470T4 (en:Method)
ES (1) ES2630002T5 (en:Method)
FI (1) FI1849470T4 (en:Method)
FR (1) FR17C1028I2 (en:Method)
HU (2) HUE033306T2 (en:Method)
LT (2) LT1849470T (en:Method)
LU (1) LUC00036I2 (en:Method)
NL (1) NL300889I2 (en:Method)
PL (1) PL1849470T5 (en:Method)
PT (1) PT1849470T (en:Method)
RU (1) RU2394581C2 (en:Method)
SI (1) SI1849470T2 (en:Method)
TW (1) TWI362265B (en:Method)
WO (1) WO2006080327A1 (en:Method)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
ES2630002T5 (es) 2005-01-26 2024-09-19 Taiho Pharmaceutical Co Ltd Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) * 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
EP2249811A1 (en) 2008-01-25 2010-11-17 Grünenthal GmbH Pharmaceutical dosage form
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
KR20120050975A (ko) 2009-07-22 2012-05-21 그뤼넨탈 게엠베하 산화-민감성 오피오이드를 위한 내변조성 용량형
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
HRP20171506T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
EP2746404B1 (en) 2011-08-16 2017-12-06 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
EP2829611A4 (en) 2012-03-14 2015-12-02 Nisshin Pharma Inc SULFURAMINOUS-SUSTAINABLE COMPOSITION
CA2868142A1 (en) 2012-04-18 2013-10-24 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
KR101848131B1 (ko) 2013-03-27 2018-04-11 다이호야쿠힌고교 가부시키가이샤 저용량 이리노테칸염산염 수화물을 함유하는 항종양제
HRP20201691T1 (hr) * 2013-03-27 2020-12-25 Taiho Pharmaceutical Co., Ltd. Antitumorni agens koji uključuje irinotekan hidroklorid hidrat
NZ714014A (en) * 2013-05-17 2017-06-30 Taiho Pharmaceutical Co Ltd Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
BR112015029616A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem resistente à adulteração com perfil de liberação bimodal
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
PL3042669T3 (pl) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
JP2017518980A (ja) 2014-05-12 2017-07-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールを含む、改変防止即時放出カプセル製剤
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
CN107889459A (zh) 2015-04-24 2018-04-06 格吕伦塔尔有限公司 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
UA125119C2 (uk) * 2016-01-08 2022-01-12 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний засіб, що містить імуномодулятор і підсилювач протипухлинного ефекту
JP6882205B2 (ja) 2016-02-05 2021-06-02 大鵬薬品工業株式会社 重度腎機能障害を有する癌患者に対する治療方法
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744475A (en) * 1995-03-29 1998-04-28 Taiho Pharmaceutical Co., Ltd. Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
PT884051E (pt) * 1996-09-24 2005-03-31 Taiho Pharmaceutical Co Ltd Inibidores de metasteses cancerosas contendo derivados de uracilo
ES2630002T5 (es) 2005-01-26 2024-09-19 Taiho Pharmaceutical Co Ltd Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa

Also Published As

Publication number Publication date
RU2394581C2 (ru) 2010-07-20
AU2006209547A1 (en) 2006-08-03
HUS1700032I1 (hu) 2017-09-28
CY2017029I2 (el) 2018-02-14
FR17C1028I1 (en:Method) 2017-09-29
ES2630002T5 (es) 2024-09-19
NL300889I1 (nl) 2017-08-14
FI1849470T4 (fi) 2024-03-22
CY1119393T1 (el) 2018-02-14
BE2017C028I2 (en:Method) 2025-09-10
CY2017029I1 (el) 2018-02-14
SI1849470T1 (sl) 2017-10-30
HUE033306T2 (hu) 2017-11-28
LUC00036I1 (en:Method) 2017-10-02
EP1849470A4 (en) 2010-12-08
LTPA2017024I1 (lt) 2017-08-10
EP1849470A1 (en) 2007-10-31
PT1849470T (pt) 2017-09-22
KR20070104559A (ko) 2007-10-26
AU2006209547B2 (en) 2011-05-26
KR101468216B1 (ko) 2014-12-03
RU2007132181A (ru) 2009-03-10
AU2006209547C1 (en) 2022-04-07
DK1849470T3 (en) 2017-08-14
FR17C1028I2 (fr) 2018-11-02
NL300889I2 (nl) 2018-01-16
SI1849470T2 (sl) 2024-05-31
LT1849470T (lt) 2017-07-25
CA2594713A1 (en) 2006-08-03
JP5576591B2 (ja) 2014-08-20
PL1849470T3 (pl) 2017-11-30
TW200637562A (en) 2006-11-01
EP1849470B2 (en) 2024-03-20
EP1849470B1 (en) 2017-06-21
JPWO2006080327A1 (ja) 2008-06-19
DK1849470T4 (en) 2024-04-02
TWI362265B (en) 2012-04-21
LUC00036I2 (en:Method) 2017-12-01
LTC1849470I2 (lt) 2019-10-25
ES2630002T3 (es) 2017-08-17
WO2006080327A1 (ja) 2006-08-03

Similar Documents

Publication Publication Date Title
LT1849470T (lt) Priešvėžinis vaistas, kurio sudėtyje yra alfa, alfa, alfa - trifluortimidinas ir timidinfosforilazės inhibitorius
PL1913001T3 (pl) (R)-N-Metylonaltrekson, sposoby jego syntezy i jego zastosowanie farmaceutyczne
SI1928882T1 (sl) (s)-n-metilnaltrekson, postopek za njega sintezo in njega farmacevtska uporaba
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
ZA200709856B (en) Fluorene derivatives,compositions containing said derivatives and the use thereof
IL194751A0 (en) Drugs and uses
SI2057153T1 (sl) (3-ril-piperazin-1-il) derivati 6,7-dialkoksikuinazolin, 6,7-dialkoksiftalazin in 6,7-dialkoksiizokuinolin
PL2034015T3 (pl) Immunostymulujący oligonukleotyd i jego zastosowanie farmaceutyczne
IL198236A0 (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
AP2008004533A0 (en) Pharmaceutical combination
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
GB0516069D0 (en) Pharmaceutical and use thereof
ZA200804666B (en) Pharmaceutical combination
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
PL1791872T3 (pl) Biotynylowane heksadekasacharydy, kompozycje farmaceutyczne i ich zastosowanie
EP1915988A4 (en) COMPRESSOR COMPRISING MULTIPLE SEGMENTS CONTAINING MEDICAMENTS
IL177759A0 (en) Cospeptin, cosmedin and their uses
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
IL191618A0 (en) N-hydroxyamide derivatives, their preparation and use
TWI372053B (en) Combination drug
AP2008004389A0 (en) Pharmaceutical combinations containing lamivudine,stavudine,stavudine and navirapine
HK1118825A (en) Substituted oxindol-derivatives, medicaments containing said derivatives and use thereof
AU2005903086A0 (en) Medicaments and uses thereof
GB0500826D0 (en) Pharmaceutical use